Tag: ETF Investing

How Does NOBL Compare To Others In This Category; SDY, VIG And WDIV?

Posted on by Matt Thalman

Matt Thalman - INO.com Contributor - ETFs


Today I would like to answer a question posed by you, a reader. A few weeks ago I mentioned one of my favorite ETF's the ProShares S&P 500 Dividend Aristocrats ETF (PACF:NOBL) and a reader named jab commented on the article and asked a question. Jab said,

"Thanks for the info on NOBL. Wasn't familiar with the term/category "dividend aristocrats." How does NOBL compare to others in this category like SDY, VIG, and WDIV?"

So, I would like to take some time and answer this question and give a little more detail on the different metrics I look for when trying to find the best ETF's to invest in when comparing similar category ETFs.

The four different ETF's we will be comparing today are the ProShares S&P 500 Dividend Aristocrats ETF, the SPDR S&P Dividend ETF (PACF:SDY), the Vanguard Dividend Appreciation Index Fund (PACF:VIG), and the SPDR S&P Global Dividend ETF (PACF:WDIV). So, let's get to it. Continue reading "How Does NOBL Compare To Others In This Category; SDY, VIG And WDIV?" →

Biotech's Upward Trend - IBB Breaks $300

Posted on by Noah Kiedrowski

Noah Kiedrowski - INO.com Contributor - Biotech


Introduction and Backdrop

As of recent, the iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) has caught an upward trend and briefly crossed the $300 per share threshold for the first time over the past 9 months. The political backdrop has been very contentious and even more so after two of the three presidential debates have wrapped up. I’ve written several pieces evaluating the massive sell-offs in the biotech sector and how extraneous events such as oil, China, interest rates and to a large extent political threats are merely noise in the larger picture. These external events provide great buying opportunities in high-quality companies or the cohort itself as represented by the sector ETF, IBB as a proxy. There’s no doubt that there’s at least a loose correlation if not a direct correlation between opportunistic political posturing by political front-runners (i.e. Hilary Clinton and Bernie Sanders) and the chronic price suppression of IBB. Each time a tweet is pushed out to social media regarding drug pricing and/or specific attacks on pharmaceutical companies, the entire cohort takes a significant hit as reflected in the price action of IBB. I contend that political posturing played a major role in the sell-off of the healthcare cohort and more specifically biotech stocks. Drug pricing was used as a centerpiece and scapegoat for political gains. Continue reading "Biotech's Upward Trend - IBB Breaks $300" →

The Aftermath Of Brexit Has Created A Buying Opportunity

Posted on by The INO.com Team

By: Joseph Hogue of Street Authority

Geopolitical issues have dominated the markets this year, and polls have been useless in lending any kind of certainty to asset prices.

OPEC has successfully managed expectations for a production freeze, even if an eventual deal is still unlikely, which has driven oil prices to nearly double since their February lows. Few would have predicted in January the momentum of the Trump campaign and the potential uncertainty on global trade.

As important as these events have been, however, 2016 will likely be remembered for one event in particular. Continue reading "The Aftermath Of Brexit Has Created A Buying Opportunity" →

3 ETFs To Buy If You Think Oil Will Continue To Rise Following OPEC's Decision

Posted on by Matt Thalman

Matt Thalman - INO.com Contributor - ETFs


Last week the Organization of the Petroleum Exporting Countries or OPEC announced that the group had to come an "agreement" to reduce oil production. The new deal slated to cut production from an estimated 33.2 million barrels per day down to 32.5 million barrels per day.

While some Wall Street analysts don't believe the production reduction will actually happen, the fact remains that since OPEC made the announcement, the price of oil is up rather dramatically. Prior to the announcement oil was trading around the $44.50 range and has since jumped to the $50 range.

Many investors are looking at the price of oil and wondering how they can get a piece of this action. Let's take a look at three Exchange Traded Funds you can buy if you believe oil prices will continue to increase. Continue reading "3 ETFs To Buy If You Think Oil Will Continue To Rise Following OPEC's Decision" →

3 ETFs 20 Somethings Should Buy

Posted on by Matt Thalman

Matt Thalman - INO.com Contributor - ETFs


There has never been a better time to be an investor. No Matter your age, investing experience, investing temperament or income level, there are a number of investment options that are right for you. I recently wrote a piece discussing a few of my favorite Exchange Traded Funds geared for all investors. Most investors should buy a few of the ETFs I mentioned in the piece or ETFs similar in nature and be set. But, after writing that piece, I began to think about how different age groups have different interests and different goals with their money and may want to further diversify their holdings based on their personal preferences.

So with that in mind, today we will be talking about three ETFs that investors in their 20's would be interested in. But before we get any further, everyone should remember the ETFs mentioned in the previous piece should still make-up a portion of your investment able assets, simply due to their stability and diversity. Continue reading "3 ETFs 20 Somethings Should Buy" →